Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,997,324
  • Shares Outstanding, K 214,054
  • Annual Sales, $ 1,882 M
  • Annual Income, $ 109,490 K
  • 36-Month Beta 1.34
  • Price/Sales 9.57
  • Price/Cash Flow 77.22
  • Price/Book 9.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +555,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.05 +12.28%
on 01/23/19
84.71 -1.85%
on 02/19/19
+4.72 (+6.02%)
since 01/18/19
3-Month
57.00 +45.86%
on 12/24/18
84.71 -1.85%
on 02/19/19
+19.55 (+30.74%)
since 11/20/18
52-Week
57.00 +45.86%
on 12/24/18
96.33 -13.69%
on 03/14/18
-2.37 (-2.77%)
since 02/20/18

Most Recent Stories

More News
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study

Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.

BAYRY : 19.4100 (+0.83%)
MRK : 79.22 (-0.03%)
INCY : 82.80 (-1.52%)
AMGN : 187.24 (+0.14%)
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

AZN : 40.71 (+0.62%)
MRK : 79.22 (-0.03%)
LLY : 121.79 (-0.28%)
INCY : 82.80 (-1.52%)
Incyte to Present at Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March:

INCY : 82.80 (-1.52%)
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer

Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.

MRK : 79.22 (-0.03%)
INCY : 82.80 (-1.52%)
AMGN : 187.24 (+0.14%)
PFE : 41.96 (-1.50%)
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat

Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

MRK : 79.22 (-0.03%)
LLY : 121.79 (-0.28%)
INCY : 82.80 (-1.52%)
NVS : 90.92 (+1.06%)
Incyte (INCY) Q4 Earnings Lag Estimates

Incyte (INCY) delivered earnings and revenue surprises of -6.98% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

INCY : 82.80 (-1.52%)
Incyte: 4Q Earnings Snapshot

WILMINGTON, Del. (AP) _ Incyte Corp. (INCY) on Thursday reported fourth-quarter net income of $69.1 million, after reporting a loss in the same period a year earlier.

INCY : 82.80 (-1.52%)
Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

--Jakafi(R) (ruxolitinib) revenues of $380 million (+26%) in 4Q2018 and $1.4 billion (+22%) for the full year 2018

INCY : 82.80 (-1.52%)
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

MGNX : 21.81 (-1.53%)
LGND : 117.50 (-1.05%)
INCY : 82.80 (-1.52%)
GILD : 66.77 (+0.01%)
SGEN : 68.84 (-1.87%)
REGN : 419.50 (-0.26%)
Incyte Corp Shares Up 19.7% Since SmarTrend's Buy Recommendation (INCY)

SmarTrend identified an Uptrend for Incyte Corp (NASDAQ:INCY) on January 3rd, 2019 at $67.01. In approximately 1 month, Incyte Corp has returned 19.71% as of today's recent price of $80.21.

INCY : 82.80 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 85.24
1st Resistance Point 84.66
Last Price 82.81
1st Support Level 83.55
2nd Support Level 83.02

See More

52-Week High 96.33
Last Price 82.81
Fibonacci 61.8% 81.31
Fibonacci 50% 76.67
Fibonacci 38.2% 72.02
52-Week Low 57.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar